Delving into the Latest Updates on Amckaus PTY LTD. with Synapse

概览

排名前五的药物类型	数量

小分子化药	1

关联

1

项与 Amckaus PTY LTD. 相关的药物

QG101-23-0

靶点-

作用机制-

在研机构

Novotech (Australia) Pty Ltd. [+1]

原研机构

Amckaus PTY LTD.

在研适应症-

非在研适应症-

最高研发阶段临床1期

首次获批国家/地区-

首次获批日期-

2

项与 Amckaus PTY LTD. 相关的临床试验

NCT05650528 / Recruiting临床1期

Single-center, Randomised, Double-blind, Placebo-controlled Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile of Single- and Multiple-dose Ascending Oral QG101-23-0 Capsules in Healthy Subjects

The study will consist of three parts: a single-dose ascending (SAD) phase (Part A) enrolling a total of five
six cohorts of healthy participants, a multiple-dose ascending (MAD) phase (Part B) enrolling 3 cohorts of healthy participants, and a food effect study (Part C).

开始日期2023-02-20

申办/合作机构

Amckaus PTY LTD.

[+1]

NCT05555758 / Recruiting临床1期

A Single-Center, Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics Profile of Aom0319 in Healthy White Subjects

Only SAD study will be conducted in this project. SAD represents single ascending dose. Multiple ascending dose have been cancelled. This decision has been made at the discretion of the Sponsor.

开始日期2022-12-15

申办/合作机构

Amckaus PTY LTD.

100 项与 Amckaus PTY LTD. 相关的临床结果

登录后查看更多信息

0 项与 Amckaus PTY LTD. 相关的专利（医药）

登录后查看更多信息

100 项与 Amckaus PTY LTD. 相关的药物交易

登录后查看更多信息

100 项与 Amckaus PTY LTD. 相关的转化医学

登录后查看更多信息